Literature DB >> 25066507

Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.

Ramūnas Janavičius1, Vilius Rudaitis2, Ugnius Mickys3, Pavel Elsakov4, Laimonas Griškevičius5.   

Abstract

There is limited knowledge about the BRCA1/2 mutational profile in Lithuania. We aimed to define the full BRCA1 and BRCA2 mutational spectrum and the clinically relevant prevalence of these gene mutations in Lithuania. A data set of 753 unrelated probands, recruited through a clinical setting, was used and consisted of 380 female breast cancer cases, 213 epithelial ovarian cancer cases, 20 breast and ovarian cancer cases, and 140 probands with positive family history of breast or ovarian cancer. A comprehensive mutation analysis of the BRCA1/2 genes by high resolution melting analysis coupled with Sanger sequencing and multiplex ligation-dependent probe amplification analysis was performed. Genetic analysis revealed 32 different pathogenic germline BRCA1/2 mutations: 20 in the BRCA1 gene and 12 in the BRCA2 gene, including four different large genomic rearrangements in the BRCA1 gene. In all, 10 novel BRCA1/2 mutations were found. Nine different recurrent BRCA1 mutations and two recurrent BRCA2 mutations were identified, which comprised 90.4% of all BRCA1/2 mutations. BRCA1 exon 1-3 deletion and BRCA2 c.658_659del are reported for the first time as recurrent mutations, pointing to a possible Baltic founder effect. Approximately 7% of breast cancer and 22% of ovarian cancer patients without family history and an estimated 0.5-0.6% of all Lithuanian women were found to be carriers of mutations in the BRCA1 or BRCA2 gene.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRCA1; BRCA2; genetic testing; hereditary breast and ovarian cancer; oncogenetics

Mesh:

Substances:

Year:  2014        PMID: 25066507     DOI: 10.1016/j.cancergen.2014.05.002

Source DB:  PubMed          Journal:  Cancer Genet


  12 in total

1.  The AIB1 gene polyglutamine repeat length polymorphism contributes to risk of epithelial ovarian cancer risk: a case-control study.

Authors:  Guoping Han; Song Xie; Hongming Fang; Gang Li; Yinquan Han; Zhen Qin
Journal:  Tumour Biol       Date:  2014-09-30

2.  Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe.

Authors:  Natalia Bogdanova; Alexandr V Togo; Magdalena Ratajska; Wojtek Kluźniak; Zalina Takhirova; Theresa Tarp; Darya Prokofyeva; Marina Bermisheva; Grigoriy A Yanus; Tatiana V Gorodnova; Anna P Sokolenko; Alina Kuźniacka; Amira Podolak; Maciej Stukan; Dominika Wokołorczyk; Jacek Gronwald; Danuta Vasilevska; Vilius Rudaitis; Ingo B Runnebaum; Matthias Dürst; Tjoung-Won Park-Simon; Peter Hillemanns; Natalia Antonenkova; Elza Khusnutdinova; Janusz Limon; Jan Lubinski; Cezary Cybulski; Evgeny Imyanitov; Thilo Dörk
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

3.  Founder vs. non-founder BRCA1/2 pathogenic alleles: the analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations.

Authors:  G A Yanus; E L Savonevich; A P Sokolenko; A A Romanko; V I Ni; E Kh Bakaeva; O A Gorustovich; I V Bizin; E N Imyanitov
Journal:  Fam Cancer       Date:  2022-05-21       Impact factor: 2.375

4.  Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation.

Authors:  Yuya Kobayashi; Shan Yang; Keith Nykamp; John Garcia; Stephen E Lincoln; Scott E Topper
Journal:  Genome Med       Date:  2017-02-06       Impact factor: 11.117

5.  Diagnostic mRNA splicing assay for variants in BRCA1 and BRCA2 identified two novel pathogenic splicing aberrations.

Authors:  Teresia Wangensteen; Caroline Nangota Felde; Deeqa Ahmed; Lovise Mæhle; Sarah Louise Ariansen
Journal:  Hered Cancer Clin Pract       Date:  2019-05-22       Impact factor: 2.857

6.  Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.

Authors:  Wenhui Li; Di Shao; Lei Li; Ming Wu; Shuiqing Ma; Xianjie Tan; Sen Zhong; Fengming Guo; Zhe Wang; Mingzhi Ye
Journal:  J Ovarian Res       Date:  2019-08-31       Impact factor: 4.234

7.  The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases.

Authors:  Gisella Figlioli; Anders Kvist; Emma Tham; Jana Soukupova; Petra Kleiblova; Taru A Muranen; Nadine Andrieu; Jacopo Azzollini; Judith Balmaña; Alicia Barroso; Javier Benítez; Birgitte Bertelsen; Ana Blanco; Bernardo Bonanni; Åke Borg; Joan Brunet; Daniele Calistri; Mariarosaria Calvello; Stepan Chvojka; Laura Cortesi; Esther Darder; Jesús Del Valle; Orland Diez; Séverine Eon-Marchais; Florentia Fostira; Francesca Gensini; Claude Houdayer; Marketa Janatova; Johanna I Kiiski; Irene Konstantopoulou; Katerina Kubelka-Sabit; Conxi Lázaro; Fabienne Lesueur; Siranoush Manoukian; Ruta Marcinkute; Ugnius Mickys; Virginie Moncoutier; Aleksander Myszka; Tu Nguyen-Dumont; Finn Cilius Nielsen; Rimvydas Norvilas; Edith Olah; Ana Osorio; Laura Papi; Bernard Peissel; Ana Peixoto; Dijana Plaseska-Karanfilska; Timea Pócza; Maria Rossing; Vilius Rudaitis; Marta Santamariña; Catarina Santos; Snezhana Smichkoska; Melissa C Southey; Dominique Stoppa-Lyonnet; Manuel Teixeira; Therese Törngren; Angela Toss; Miguel Urioste; Ana Vega; Zdenka Vlckova; Drakoulis Yannoukakos; Valentina Zampiga; Zdenek Kleibl; Paolo Radice; Heli Nevanlinna; Hans Ehrencrona; Ramunas Janavicius; Paolo Peterlongo
Journal:  Cancers (Basel)       Date:  2020-01-26       Impact factor: 6.639

8.  Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea.

Authors:  Jun Hyeong Seo; Soo Young Jeong; Myeong Seon Kim; Jun Hyeok Kang; E Sun Paik; Yoo-Young Lee; Tae-Joong Kim; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae; Chel Hun Choi
Journal:  Obstet Gynecol Sci       Date:  2019-10-11

9.  A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review.

Authors:  P Loza; A Irmejs; Z Daneberga; E Miklasevics; E Berga-Svitina; S Subatniece; J Maksimenko; G Trofimovics; E Tauvena; S Ukleikins; J Gardovskis
Journal:  Hered Cancer Clin Pract       Date:  2021-01-19       Impact factor: 2.857

10.  Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study.

Authors:  Muhammad Usman Rashid; Noor Muhammad; Humaira Naeemi; Faiz Ali Khan; Mariam Hassan; Saima Faisal; Sidra Gull; Asim Amin; Asif Loya; Ute Hamann
Journal:  Hered Cancer Clin Pract       Date:  2019-09-11       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.